Status:
COMPLETED
Extended Open Challenge in Patients With a History of Drug Eruption Following Beta-lactam Treatment
Lead Sponsor:
Meir Medical Center
Conditions:
Beta-lactam Allergy
Eligibility:
All Genders
Phase:
NA
Brief Summary
Beta-lactam allergy is the most prevalent drug allergy. Drug eruption is the most common symptom whereas life-threatening anaphylaxis is rather rare. A recently published study (Journal of Allergy and...
Eligibility Criteria
Inclusion
- History of skin rash following the administration of beta-lactam antibiotic
- Patients with a diagnosis of penicillin allergy who have no data on the nature of the symptoms that have eventually resulted in establishing this diagnosis
Exclusion
- Patients in whom the rash appeared within 1 hour after the last dose of the drug
- Patients who also developed other anaphylactic symptoms
- Patients who had a life-threatening rash such as Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis or DRESS.
- Pregnancy
Key Trial Info
Start Date :
March 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2015
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT01520181
Start Date
March 1 2012
End Date
June 1 2015
Last Update
October 7 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Arnon Goldberg, Allergy and Clinical Unit, Meir Medical Center
Kfar Saba, Israel, 44281